Pregnant women diagnosed with malaria are randomised to receive either amodiaquine-artesunate ( AQ-AS ) , dihydroartemisinin-piperaquine ( DHA-PQ ) , artemether-lumefantrine ( AL ) , or mefloquine-artesunate ( MQAS ) .